ENB Therapeutics is a clinical stage privately held company developing therapies to treat drug resistant cancers by reprogramming the tumor microenvironment. Our lead product, ENB-003, is a First-in-Class, small molecule, selective endothelin B receptor inhibitor that overcomes immunotherapy resistance across multiple cancer indications in preclinical studies. ENB-003 dramatically enhances CAR-T efficacy in a triple negative breast cancer model, eradicating most tumors within 3 weeks. In our ongoing international Phase 1 trial in collaboration with Merck, ENB-003, in combination with pembrolizumab, is well tolerated and demonstrates encouraging efficacy signals in drug refractory, heavily pre-treated pancreatic cancer, ovarian cancer and melanoma. ENB-003 is the key to unlocking new therapeutic markets in indications that do not respond to immunotherapies such as anti-PD1/PDL1, CTLA-4, CAR-T and cancer vaccines. We are currently raising a Series B round to support our Phase 2 trial.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Oncology
Lead Product in Development:
ENB-003
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
